Stockreport

Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF The call came days after the rare-disease drug developer reported 2023 fourth-quarter earnings, which caused the market to dump its shares to the tune of 13%. Here's w [Read more]